Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults
Blume, K.G.; Beutler, E.; Chillar, R.K.; Fahey, J.L.; Sharkoff, D.; Zia, P.K.
JAMA 239(20): 2149-2151
1978
ISSN/ISBN: 0098-7484 PMID: 642157 Document Number: 126907
Adult patients with chronic iron overload were given oral ascorbic acid and continuous intravenous infusions of deferoxamine mesylate. The dosage of deferoxamine mesylate was altered every 48 hours from 1 g/sq m/24 hr to 2 or 4 g/sq m/24 hr. The average iron mobilization was 55.6 mg per day at the 1 g/sq m/24 hr dosage level, 78.6 mg every 24 hours at the 2 g/sq m/24 hr dosage level, and 90.1 mg every 24 hours at the 4 g/sq m/24 hr dosage level. Iron mobilization was undiminished when successive 14-day courses of deferoxamine separated by six-week intervals were administered.